| |
|
|
|
|
|
|
|||
|
Blood, 1 February 2008, Vol. 111, No. 3, pp. 1054-1059. Prepublished online as a Blood First Edition Paper on November 7, 2007; DOI 10.1182/blood-2007-08-099168.
CLINICAL TRIALS AND OBSERVATIONS Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia1 Department of Pediatrics, Hyogo Children Hospital, Hyogo; 2 Department of Pediatrics, Nagoya University Graduate School of Medicine, Aichi; 3 Department of Pediatrics, Kobe University Graduate School of Medicine, Hyogo; 4 Department of Pediatrics, Hokkaido University Graduate School of Medicine, Hokkaido; 5 Department of Pediatrics, Yamaguchi University School of Medicine, Yamaguchi; 6 Department of Pediatrics, Kiyose Children's Hospital, Tokyo; 7 Specialized Clinical Science, Pediatrics, Tokai University School of Medicine, Kanagawa; 8 Department of Pediatrics, Ibaraki Children's Hospital, Ibaraki; 9 Department of Pediatrics, Nihon University School of Medicine, Tokyo; 10 Department of Transfusion, Toho University School of Medicine, Tokyo; 11 Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto; 12 Department of Pediatrics, Hyogo College of Medicine, Hyogo; 13 Department of Pediatrics, Kyushu University Graduate School of Medicine, Fukuoka; 14 Department of Pediatrics, Kyorin University School of Medicine, Tokyo; 15 Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto; and 16 Department of Pediatrics, Toho University School of Medicine, Tokyo, Japan We conducted a prospective multicenter study to compare the efficacy of repeated immunosuppressive therapy (IST) with stem-cell transplantation (SCT) from an alternative donor in children with acquired aplastic anemia (AA) who failed to respond to an initial course of IST. Patients with severe (n = 86) and very severe disease (n = 119) received initial IST consisting of antithymocyte globulin (ATG) and cyclosporine. Sixty patients failed to respond to IST after 6 months from the initial IST and were eligible for second-line treatment. Among them, 21 patients lacking suitable donors received a second course of IST. Three patients developed an anaphylactoid reaction to ATG and could not complete the second IST. A trilineage response was seen in only 2 of 18 (11%) evaluable patients after 6 months. Thirty-one patients received SCT from an alternative donor. At 5 years from the initiation of second-line therapy, the estimated failure-free survival (FFS), defined as survival with response, was 83.9% (± 16.1%, SD) in the SCT group compared with 9.5% (± 9.0%) in the IST group (P = .001). These results suggest that SCT from an alternative donor offers a better chance of FFS than a second IST in patients not responding to an initial IST.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||